<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185613</url>
  </required_header>
  <id_info>
    <org_study_id>AF-09-024-EU-AB</org_study_id>
    <nct_id>NCT01185613</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>FACT-AF</acronym>
  <official_title>Clinical Evaluation of Therapy™ Cool Flex Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the performance of Therapy™ Cool Flex™ catheter by&#xD;
      documenting the procedural parameters, major complications and recurrence of AF after&#xD;
      ablation using Cool Flex ablation catheter for the treatment of paroxysmal atrial&#xD;
      fibrillation.&#xD;
&#xD;
      This study is an observational clinical study which is not based on any specific endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Ablation parameters (such as average power delivered , average tip temperature , average impedance )&#xD;
Lesion locations (such as PVI, Septal line, Mitral isthmus, CTI or any other lesion location)&#xD;
Mapping techniques (Mapping system and catheter)&#xD;
RF application time ( Calculated from the total number of RF application and duration of each RF application)&#xD;
Ablation procedure time (Time from the first to the last RF application)&#xD;
Total irrigation fluid administered during ablation procedure&#xD;
Fluoroscopy time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AF Recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>Recurrence of AF through six months post last RF ablation procedure using Cool Flex catheter. A 24 hour Holter will be provided to the patients for six month follow-up visit in order to monitor AF episodes. An AF episode will be considered a recurrence only if it lasts for 30 seconds or more.&#xD;
AF recurrences during the blanking period (defined below) will not be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>All serious adverse events through six month follow-up</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Therapy™ Cool Flex Ablation Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapy™ Cool Flex Ablation Catheter</intervention_name>
    <description>The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.&#xD;
The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter&#xD;
IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.&#xD;
Cool Point™ Irrigation Pump&#xD;
Cool Point™ Tubing set&#xD;
Data Logger</description>
    <arm_group_label>Therapy™ Cool Flex Ablation Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A signed written Informed Consent form&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Agrees to comply with follow-up visits and evaluation&#xD;
&#xD;
          -  Candidate for catheter ablation for the treatment of paroxysmal atrial fibrillation as&#xD;
             per the hospital standard of care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persistent or Long standing AF&#xD;
&#xD;
          -  CABG procedure within the last 180 days (six months).&#xD;
&#xD;
          -  Documented left atrial thrombus on imaging [e.g. Transesophageal echocardiogram&#xD;
             (TEE)].&#xD;
&#xD;
          -  History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
          -  Contraindication to anticoagulation (i.e. heparin or warfarin).&#xD;
&#xD;
          -  Enrollment in another investigational study evaluating device or drug that might&#xD;
             impact the results of this study.&#xD;
&#xD;
          -  Women who are pregnant (by history of menstrual period or pregnancy test if the&#xD;
             history is considered unreliable).&#xD;
&#xD;
          -  Acute illness or active systemic infection or sepsis.&#xD;
&#xD;
          -  Life expectancy less than 12 months.&#xD;
&#xD;
          -  Uncontrolled heart failure or NYHA class IV heart failure.&#xD;
&#xD;
          -  Myocardial Infarction within 8 weeks of enrollment or unstable angina&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Leipzig Herzzentrum</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospendale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Cruz</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <name_title>Christophe Bailleul</name_title>
    <organization>SJM International, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

